Serological and immunohistopathological studies on the effect of radiation on tumor-host relationship

1. (1)血清SCC抗原水平的测定：恶性肿瘤患者血清SCC水平为19%，各种非恶性疾病患者血清SCC水平为8%，健康对照为0%。食管癌、宫颈癌、肺癌、皮肤癌和阴道及外阴癌患者血清中SCC水平较高。根据组织学类型，分化型鳞状细胞癌的血清SCC抗原水平高于其他组织学类型。放疗后升高的血清SCC抗原水平迅速降至正常水平。免疫增强剂最佳给药方法的研究(1)临床研究esps - k在放疗后每月2周，每天口服3.0g，间歇给药。PS-K是有效的间歇给药，当患者一般情况良好时，停药期应在2个月内。(2)实验研究采用组织病理学方法研究了PS-K对小鼠淋巴组织的影响。在网状内皮系统中观察到明显的变化，表明PS-K的作用。网状内皮系统激活后可见明显的无结构样半透明物质。I-131标记抗CEA和抗CA 19-9单克隆抗体（IMACIS 1）免疫显像评价的研究临床86例中有66例（77%）显像阳性。阳性比值与肿瘤大小有显著相关。给人肺癌裸鼠注射IMACIS 1。然后得到阳性闪烁图。

1. Studies on immunological changes by iiradiation in tumor-bearing hosts(1) Determinations of serum SCC antigen levelPositive rate of serum SCC level was 19% in patients with malignant tumors, 8% with various non-malignant diseases and 0% in healthy control. High serum levels of SCC were found in patients with esophageal cancer, cervical cancer, pulmonary cancer skin cancer and vaginal & vulval cancer. According to the histological types, differentiated squamous cell carcinoma appeard to produce a higher serum level of SCC antigen than other histological types. Elevated serum levels of SCC antigen rapidly decreased to a normal level after radio-therapy.2. Studies on the optimal administration method of an immunopotentiator(1) Clinical studiesPS-K was given orally 3.0g per day intermittently in the pattern of 2 weeks per month after radiation therapy. Intermittent administration of PS-K is effective and the period of withdrawal of the drug should be within 2 months when the patient is under good general condition.(2) Experimental studiesThe effects of PS-K on mice were studied histopathologically in lymphoid tissues in longest period and also when used with radiation. Distinctive changes which indicated the effects of PS-K were observed in reticuloendo-thelial system. Appearance of an obvious structureless-like translucentsub-stance followed the activation of the reticuloendothelial system.3. Studies on evaluation of immunoscintigraphy using I-131 labeled anti CEA and anti CA 19-9 monoclonal antibody(IMACIS 1)The positive scintigraphies were obtained in 66 of 86 cases(77%) clinically. There was significant correlation of positive ratio with tumor size.The nude mice that were bearing human lung cancer were recieved administration of IMACIS 1. Then the positive scintigraphies were obtained.